论文部分内容阅读
目的:评价不同剂量重组人生长激素对特发性矮小症患儿的临床疗效。方法:选取2010年10月—2012年10月间收治的特发性矮小症患儿84例,将其随机均分为高剂量组0.2 U/(kg·d)、中剂量组0.15 U/(kg·d)和低剂量组0.1 U/(kg·d),各28例;比较三组患儿治疗后的临床疗效及不良反应的发生情况。结果:高剂量组和中剂量组经治疗后,患儿身高、生长速率均明显高于低剂量组(P<0.05);三组患儿骨龄指数增长值经比较其差异无统计学意义(P>0.05);高剂量组患儿不良反应的发生率为21.43%高于中剂量组为7.14%(P>0.05)。结论:中剂量重组人生长激素对特发性矮小症患儿的临床疗效较确切,且临床不良反应的发生率较低。
Objective: To evaluate the clinical efficacy of different doses of recombinant human growth hormone in children with idiopathic short stature. Methods: Eighty-four children with idiopathic short stature admitted to our hospital from October 2010 to October 2012 were randomly divided into high dose group (0.2 U / (kg · d)) and middle dose group (0.15 U / ( kg · d) and low dose group (0.1 U / (kg · d), 28 cases each). The clinical efficacy and adverse reactions of the three groups were compared. Results: After treatment, the height and growth rate of children in high-dose group and medium-dose group were significantly higher than those in low-dose group (P <0.05). There was no significant difference in the value of bone age index between the three groups > 0.05). The incidence of adverse reactions in high dose group was 21.43% higher than that in middle dose group (7.14%, P> 0.05). CONCLUSION: The medium dose of recombinant human growth hormone has a definite clinical effect on idiopathic short stature, and the incidence of clinical adverse reactions is low.